The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Structure-based design of targeted covalent inhibitors
Abstract
Covalent inhibition is a rapidly growing discipline within drug discovery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with noncovalent inhibitors, covalent PPI inhibitors can have the advantages of sustained inhibition and longer residence times, as covalently bound PPI targets are persistently inhibited until protein degradation and regeneration [40].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [40]
In the citing paper
“Covalent ligand screening is another ligand discovery approach that is becoming more common, whereby various methods are used to discover covalent ligands from libraries of electrophilic compounds7,12,13.”
From Advances in covalent drug discovery (2022) · cites this paper as [7]
In the citing paper
“include the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (AbbVie) and the epidermal growth factor receptor (EGFR) inhibitor osimertinib (AstraZeneca), with sales totalling US$8.43 billion and $4.33 billion in 2020, respectively7,8.”
From Advances in covalent drug discovery (2022) · cites this paper as [7]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Self-citationComputational Methods in Drug Discovery
Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007336 · Cited by 2,160
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Wang, L., Wu, Y., Deng, Y., Kim, B., Pierce, L., Krilov, G., Lupyan, D., Robinson, S., Dahlgren, M. K., Greenwood, J., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/ja512751q · Cited by 1,313
Proteome-wide covalent ligand discovery in native biological systems
Backus, K. M., Correia, B. E., Lum, K. M., Forli, S., Horning, B. D., González-Páez, G. E., Chatterjee, S., Lanning, B. R., Teijaro, J. R., Olson, A. J., et al. (2016) · Nature · doi:10.1038/nature18002 · Cited by 940
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Combined Quantum Mechanics/Molecular Mechanics (QM/MM) Methods in Computational Enzymology
van der Kamp, M. W., & Mulholland, A. J. (2013) · Biochemistry · doi:10.1021/bi400215w · Cited by 635
Augeri, D. J., Robl, J. A., Betebenner, D. A., Magnin, D. R., Khanna, A., Robertson, J. G., Wang, A., Simpkins, L. M., Taunk, P., Huang, Q., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050261p · Cited by 624
Jackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Redox-based reagents for chemoselective methionine bioconjugation
Lin, S., Yang, X., Jia, S., Weeks, A. M., Hornsby, M., Lee, P. S., Nichiporuk, R. V., Iavarone, A. T., Wells, J. A., Toste, F. D., et al. (2017) · Science · doi:10.1126/science.aal3316 · Cited by 513
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
Gauthier, J. Y., Chauret, N., Cromlish, W., Desmarais, S., Duong, L. T., Falgueyret, J.-P., Kimmel, D. B., Lamontagne, S., Léger, S., LeRiche, T., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.047 · Cited by 477
Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12022 · Cited by 418
Barf, T., Covey, T., Izumi, R., van de Kar, B., Gulrajani, M., van Lith, B., van Hoek, M., de Zwart, E., Mittag, D., Demont, D., et al. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242909 · Cited by 380
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Barf, T., & Kaptein, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003203 · Cited by 331
Flanagan, M. E., Abramite, J. A., Anderson, D. P., Aulabaugh, A., Dahal, U. P., Gilbert, A. M., Li, C., Montgomery, J., Oppenheimer, S. R., Ryder, T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501412a · Cited by 320
Covalent docking of large libraries for the discovery of chemical probes
London, N., Miller, R. M., Krishnan, S., Uchida, K., Irwin, J. J., Eidam, O., Gibold, L., Cimermančič, P., Bonnet, R., Shoichet, B. K., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1666 · Cited by 274
Lysine‐Targeting Covalent Inhibitors
Pettinger, J., Jones, K., & Cheeseman, M. D. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707630 · Cited by 236
Quantification and Theoretical Analysis of the Electrophilicities of Michael Acceptors
Allgäuer, D. S., Jangra, H., Asahara, H., Li, Z., Chen, Q., Zipse, H., Ofial, A. R., & Mayr, H. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b05106 · Cited by 232
Covalent protein modification: the current landscape of residue-specific electrophiles
Shannon, D. A., & Weerapana, E. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.10.021 · Cited by 230
Cathepsin K inhibitors for osteoporosis and potential off-target effects
Brömme, D., & Lecaille, F. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902832661 · Cited by 216
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain
Akçay, G., Belmonte, M. A., Aquila, B., Chuaqui, C., Hird, A. W., Lamb, M. L., Rawlins, P. B., Su, N., Tentarelli, S., Grimster, N. P., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2174 · Cited by 207
Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors
Miller, R. M., Paavilainen, V. O., Krishnan, S., Serafimova, I. M., & Taunton, J. (2013) · Journal of the American Chemical Society · doi:10.1021/ja401221b · Cited by 191
Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity
Lonsdale, R., Burgess, J., Colclough, N., Davies, N. L., Lenz, E. M., Orton, A. L., & Ward, R. A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00553 · Cited by 190
Self-citationMukherjee, H., Debreczeni, J., Breed, J., Tentarelli, S., Aquila, B., Dowling, J. E., Whitty, A., & Grimster, N. P. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02028g · Cited by 167
Crystal structure of human cathepsin K complexed with a potent inhibitor
McGrath, M. E., Klaus, J. L., Barnes, M., & Brömme, D. (1997) · Nature Structural Biology · doi:10.1038/nsb0297-105 · Cited by 152
Dalton, S. E., Dittus, L., Thomas, D. A., Convery, M. A., Nunes, J., Bush, J. T., Evans, J. P., Werner, T., Bantscheff, M., Murphy, J. A., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08979 · Cited by 141
Identification and Characterization of an Irreversible Inhibitor of CDK2
Anscombe, E., Meschini, E., Mora-Vidal, R., Martin, M. P., Staunton, D., Geitmann, M., Danielson, U. H., Stanley, W. A., Wang, L.-Z., Reuillon, T. D., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.018 · Cited by 134
Determining Cysteines Available for Covalent Inhibition Across the Human Kinome
Zhao, Z., Liu, Q., Bliven, S. E., Xie, L., & Bourne, P. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01815 · Cited by 134
Prospective Evaluation of Free Energy Calculations for the Prioritization of Cathepsin L Inhibitors
Kuhn, B., Tichý, M., Wang, L., Robinson, S. D., Martin, R. E., Kuglstatter, A., Benz, J., Giroud, M., Schirmeister, T., Abel, R., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01881 · Cited by 133
Evaluation of Methods for the Calculation of the p K a of Cysteine Residues in Proteins
Awoonor‐Williams, E., & Rowley, C. N. (2016) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6b00631 · Cited by 123
Singh, J., Dobrusin, E. M., Fry, D. W., Haske, T., Whitty, A., & McNamara, D. J. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960380s · Cited by 115
Shibata, Y., & Chiba, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061424 · Cited by 111
A Classical Enzyme Active Center Motif Lacks Catalytic Competence until Modulated Electrostatically
Pinitglang, S., Watts, A. B., Patel, M., Reid, J. D., Noble, M. A., Gul, S., Bokth, A., Naeem, A., Patel, H., Thomas, E. W., et al. (1997) · Biochemistry · doi:10.1021/bi9705974 · Cited by 99
Expanding the scope of electrophiles capable of targeting K-Ras oncogenes
McGregor, L. M., Jenkins, M. L., Kerwin, C., Burke, J. E., & Shokat, K. M. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00271 · Cited by 97
Modeling covalent-modifier drugs.
Awoonor-Williams, E., Walsh, A. G., & Rowley, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.05.009 · Cited by 90
Ma, S., Devi-Kesavan, L. S., & Gao, J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja074222+ · Cited by 89
Guo, Z., Li, B., Cheng, L., Zhou, S., McCammon, J. A., & Che, J. (2015) · Journal of Chemical Theory and Computation · doi:10.1021/ct500867u · Cited by 80
Dahal, U. P., Gilbert, A. M., Obach, R. S., Flanagan, M. E., Chen, J. M., García-Irizarry, C. N., Starr, J. T., Schuff, B. P., Uccello, D. P., & Young, J. A. (2016) · MedChemComm · doi:10.1039/c6md00017g · Cited by 75
Wu, S., Luo, H., Wang, H., Zhao, W., Hu, Q., & Yang, Y. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.109 · Cited by 51
Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches
Zhang, Y., Zhang, D., Tian, H.-Z., Jiao, Y., Shi, Z., Ran, T., Liu, H., Lü, S., Xu, A., Qiao, X., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00302 · Cited by 35
Shokhen, M., Hirsch, M., Khazanov, N., Ozeri, R., Perlman, N., Traube, T., Vijayakumar, S., & Albeck, A. (2014) · Israel Journal of Chemistry · doi:10.1002/ijch.201300144 · Cited by 11
The art and practice of structure-based drug design: A molecular modeling perspective
(1996) · doi:10.1002/(sici)1098-1128(199601)16:1<3::aid-med1>3.0.co;2-6
Research works printed but not linked: 1
- Martin-Gago, 2017, Cell Chem. Biol., 24, e585
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
Put a ring on it: application of small aliphatic rings in medicinal chemistry
Bauer, M. R., Di Fruscia, P., Lucas, S. C. C., Michaelides, I. N., Nelson, J. E., Storer, R. I., & Whitehurst, B. C. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00370k · Cited by 479
Advances in covalent kinase inhibitors
Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 317
Metadata
- Authors
- Lonsdale, R., & Ward, R. A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Ward, Richard A.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2018
- Volume
- 47
- Issue
- 11
- Pages
- 3816-3830
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W2796108867
- Cited by
- 344
- References
- 49
- Citations by year
- 2026: 30 · 2025: 42 · 2024: 46 · 2023: 49 · 2022: 47 · 2021: 45 · 2020: 46 · 2019: 31 · 2018: 8
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- targeted covalent inhibitors, covalent inhibition, structure-based drug design, reactive functional groups, small molecule inhibitors, inhibitor selectivity, covalent drug discovery
- MeSH terms
- Humans, Drug Design, Molecular Structure, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.